All Zevaskyn (prademagene zamikeracel) articles
-
NewsKrystal Biotech wins MHRA approval for genetic medicine Vyjuvek
Authorisation expands treatment options for UK patients with the rare genetic skin condition dystrophic epidermolysis bullosa.
-
NewsFDA approves first-of-a-kind gene therapy for dystrophic epidermolysis bullosa
With clinical data showing the gene therapy can address large and challenging chronic wounds, the FDA’s decision will help improve quality of life for dystrophic epidermolysis bullosa (DEB) patients.